Chelsea Therapeutics International, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chelsea Therapeutics International, Ltd.
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
In this week's podcast edition of Five Must-Know Things: new AstraZeneca ADC lung cancer data seen as underwhelming; William Pao’s aspirations at Pfizer; Scholar Rock’s hopes for SMA asset; Biomarin’s Roctavian launch; and Indian lighthouses deliver gains.
Phase III study under way may lead to filing of drug meant to address muscular component of the rare disease, with existing therapies such as Spinraza targeting neurological aspects.
News We’re Watching: New CDC Director, Endologix Study Success, Hospital Closure Linked To Ransomware
This week, North Carolina health secretary Mandy Cohen was named the new head of the CDC; Congress debated PAHPA reauthorization; Cala Health launched a Parkinson’s Disease wearable; and IHealth.io was fined for consumer privacy violations.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.